Beyond Air, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US08862L1035
USD
1.28
0.14 (12.28%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

145.08 k

Shareholding (Dec 2024)

FII

1.65%

Held by 21 FIIs

DII

92.79%

Held by 8 DIIs

Promoter

0.00%

How big is Beyond Air, Inc.?

22-Jun-2025

As of Jun 18, Beyond Air, Inc. has a market capitalization of 24.62 million and reported net sales of 3.02 million with a net profit loss of 54.97 million over the latest four quarters.

As of Jun 18, Beyond Air, Inc. has a market capitalization of 24.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 3.02 million for the latest four quarters. During the same period, it experienced a net profit loss of 54.97 million.<BR><BR>As of Mar 24, the reporting period for the balance sheet shows shareholder's funds of 25.05 million and total assets amounting to 56.96 million.

Read More

What does Beyond Air, Inc. do?

22-Jun-2025

Beyond Air, Inc. is a medical device company developing a nitric oxide generator and delivery system for the Pharmaceuticals & Biotechnology industry. As of December 2024, it reported net sales of $1 million and a net loss of $13 million, with a market cap of $24.62 million.

Overview:<BR>Beyond Air, Inc. is a medical device company focused on developing a nitric oxide generator and delivery system for the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 1 Million (Quarterly Results - Dec 2024)<BR>- Most recent Net Profit: -13 Million (Quarterly Results - Dec 2024)<BR>- Market cap: USD 24.62 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.22<BR>- Return on Equity: -350.33%<BR>- Price to Book: 1.81<BR><BR>Contact Details:<BR>- Address: 825 E Gate Blvd Ste 320, GARDEN CITY NY: 11530-2135<BR>- Tel: 1 516 6658200<BR>- Website: http://www.ait-pharm.com

Read More

Should I buy, sell or hold Beyond Air, Inc.?

22-Jun-2025

Who are in the management team of Beyond Air, Inc.?

22-Jun-2025

As of March 2022, the management team of Beyond Air, Inc. includes Steven Lisi (Chairman and CEO), Amir Avniel (President and COO), and independent directors Ron Bentsur, Robert Carey, William Forbes, Yoori Lee, and Erick Lucera. They are responsible for the company's strategic direction and operations.

As of March 2022, the management team of Beyond Air, Inc. includes the following individuals:<BR><BR>- Mr. Steven Lisi, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Amir Avniel, who is the President, Chief Operating Officer, and a Director.<BR>- The Board of Directors also includes independent directors: Mr. Ron Bentsur, Mr. Robert Carey, Dr. William Forbes, Ms. Yoori Lee, and Mr. Erick Lucera. <BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Read More

Is Beyond Air, Inc. overvalued or undervalued?

20-Sep-2025

As of June 24, 2024, Beyond Air, Inc. is rated as risky due to overvaluation and significant financial distress, reflected in poor key ratios and a year-to-date stock performance decline of 68.06%, contrasting sharply with the S&P 500's 12.22% gain.

As of 24 June 2024, the valuation grade for Beyond Air, Inc. has moved from does not qualify to risky. The company appears to be overvalued based on its current metrics. Key ratios include a Price to Book Value of 0.93, an EV to EBIT of -0.29, and an EV to EBITDA of -0.31, all indicating significant financial distress and inefficiency.<BR><BR>In comparison to peers, Beyond Air, Inc. has a less favorable EV to EBITDA ratio than Perspective Therapeutics, Inc. at -0.7951 and a stark contrast to Electromed, Inc., which has a fair valuation with an EV to EBITDA of 17.5033. The company's stock has underperformed significantly, with a year-to-date return of -68.06% compared to the S&P 500's gain of 12.22%, highlighting its struggles in the market.

Read More

Is Beyond Air, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Beyond Air, Inc. shows a bullish trend despite mixed technical signals and significant underperformance, with year-to-date returns of -68.06% compared to the S&P 500's 12.22%.

As of 3 September 2025, the technical trend for Beyond Air, Inc. has changed from mildly bullish to bullish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mild bullishness. However, the daily moving averages are bearish, and the weekly KST is bearish, which contrasts with the monthly KST being mildly bullish. The Bollinger Bands and Dow Theory suggest bearish conditions on the weekly and monthly time frames. <BR><BR>Despite the bullish trend change, the stock has significantly underperformed compared to the S&P 500, with year-to-date returns of -68.06% versus the S&P 500's 12.22%. Overall, the current technical stance is bullish but with mixed signals and significant underperformance in the longer term.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Positive results in Jun 25

  • NET SALES(HY) At USD 2.91 MM has Grown at 152.56%
  • OPERATING CASH FLOW(Y) Highest at USD -32.57 MM
  • DEBTORS TURNOVER RATIO(HY) Highest at 5.7 times
2

Risky - Negative EBITDA

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.37

stock-summary
Return on Equity

-416.52%

stock-summary
Price to Book

1.74

Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-8 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-44.59%
0%
-44.59%
6 Months
-65.92%
0%
-65.92%
1 Year
-88.3%
0%
-88.3%
2 Years
-96.14%
0%
-96.14%
3 Years
-79.52%
0%
-79.52%
4 Years
-99.53%
0%
-99.53%
5 Years
-98.79%
0%
-98.79%

Beyond Air, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
36.79%
EBIT Growth (5y)
-31.48%
EBIT to Interest (avg)
-21.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
37.25%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.93
EV to EBIT
-0.29
EV to EBITDA
-0.31
EV to Capital Employed
0.92
EV to Sales
4.75
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-320.24%
ROE (Latest)
-299.26%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 16 Schemes (5.56%)

Foreign Institutions

Held by 21 Foreign Institutions (1.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 50.00% vs 9.09% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 39.10% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.80",
          "val2": "1.20",
          "chgp": "50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-6.20",
          "chgp": "-8.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.10",
          "val2": "-8.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,327.80%",
          "val2": "-6,226.60%",
          "chgp": "189.88%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 208.33% vs 0.00% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 24.57% vs -8.25% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.70",
          "val2": "1.20",
          "chgp": "208.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.00",
          "val2": "-60.70",
          "chgp": "32.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.00",
          "val2": "2.90",
          "chgp": "3.45%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "0.10",
          "chgp": "-1,000.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-48.50",
          "val2": "-64.30",
          "chgp": "24.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,020.80%",
          "val2": "-54,363.20%",
          "chgp": "4,234.24%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
1.80
1.20
50.00%
Operating Profit (PBDIT) excl Other Income
-6.70
-6.20
-8.06%
Interest
0.50
0.60
-16.67%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-8.10
-8.10
Operating Profit Margin (Excl OI)
-4,327.80%
-6,226.60%
189.88%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 50.00% vs 9.09% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 39.10% in Mar 2025

Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
3.70
1.20
208.33%
Operating Profit (PBDIT) excl Other Income
-41.00
-60.70
32.45%
Interest
3.00
2.90
3.45%
Exceptional Items
-0.90
0.10
-1,000.00%
Consolidate Net Profit
-48.50
-64.30
24.57%
Operating Profit Margin (Excl OI)
-12,020.80%
-54,363.20%
4,234.24%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 208.33% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 24.57% vs -8.25% in Mar 2024

stock-summaryCompany CV
About Beyond Air, Inc. stock-summary
stock-summary
Beyond Air, Inc.
Pharmaceuticals & Biotechnology
Beyond Air, Inc., formerly AIT Therapeutics, Inc., is a medical device company. The Company is focused on developing a nitric oxide (NO) generator and delivery system that generates NO from ambient air. The Beyond Air NOGDS is designed to deliver a dosage of NO to the lungs. The Company focuses on areas, such as persistent pulmonary hypertension of the newborn (PPHN), bronchiolitis (BRO) and nontuberculous mycobacteria (NTM). Its Beyond Air NOGDS also delivers a high concentration of NO to the lungs. The Company’s products include Beyond Air- PH, Beyond Air- BRO and Beyond Air- NTM.
Company Coordinates stock-summary
Company Details
825 E Gate Blvd Ste 320 , GARDEN CITY NY : 11530-2135
stock-summary
Tel: 1 516 6658200
stock-summary
Registrar Details